Eisai presented latest data from the lecanemab clinical program at AAIC 2021

BioArctic AB’s partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, Colorado July 26 to 30, 2021. The presentations included the latest data for the investigational anti-amyloid beta antibody lecanemab (BAN2401), for which the FDA granted Breakthrough Therapy designation in June 2021.